Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisa Genuardi

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Diagnostics (Basel, Switzerland)|April 30, 2021
MYD88<sup>L265P</sup> Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine ImplementationMartina Ferrante, Daniela Furlan, Silvia Zibellini, et al.
The Journal of Molecular Diagnostics : JMD|August 31, 2015
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCRDaniela Drandi, Lenka Kubiczkova-Besse, Simone Ferrero, et al.
JCO Clinical Cancer Informatics|October 22, 2019
Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical OutcomesGian Maria Zaccaria, Simone Ferrero, Samanta Rosati, et al.
Haematologica|March 24, 2018
Highly sensitive <i>MYD88</i><sup>L265P</sup> mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemiaDaniela Drandi, Elisa Genuardi, Irene Dogliotti, et al.
Hematological Oncology|July 21, 2019
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD NetworkIrene Della Starza, Marzia Cavalli, Lucia Anna De Novi, et al.
Hematological Oncology|March 20, 2021
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphomaElisa Genuardi, Petra Klous, Barbara Mantoan, et al.
Mechanisms of Ageing and Development|June 13, 2012
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartmentChiara Lobetti-Bodoni, Dario Ferrero, Elisa Genuardi, et al.
Blood|October 3, 2013
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive programMarco Ladetto, Chiara Lobetti-Bodoni, Barbara Mantoan, et al.
Eclinicalmedicine|July 3, 2023
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencingStefania Oliva, Elisa Genuardi, Laura Paris, et al.
Hematological Oncology|August 21, 2020
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphomaIrene Della Starza, Lucia Anna De Novi, Marzia Cavalli, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Diagnostics (Basel, Switzerland)|April 30, 2021
MYD88<sup>L265P</sup> Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine ImplementationMartina Ferrante, Daniela Furlan, Silvia Zibellini, et al.
The Journal of Molecular Diagnostics : JMD|August 31, 2015
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCRDaniela Drandi, Lenka Kubiczkova-Besse, Simone Ferrero, et al.
JCO Clinical Cancer Informatics|October 22, 2019
Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical OutcomesGian Maria Zaccaria, Simone Ferrero, Samanta Rosati, et al.
Haematologica|March 24, 2018
Highly sensitive <i>MYD88</i><sup>L265P</sup> mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemiaDaniela Drandi, Elisa Genuardi, Irene Dogliotti, et al.
Hematological Oncology|July 21, 2019
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD NetworkIrene Della Starza, Marzia Cavalli, Lucia Anna De Novi, et al.
Hematological Oncology|March 20, 2021
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphomaElisa Genuardi, Petra Klous, Barbara Mantoan, et al.
Mechanisms of Ageing and Development|June 13, 2012
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartmentChiara Lobetti-Bodoni, Dario Ferrero, Elisa Genuardi, et al.
Blood|October 3, 2013
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive programMarco Ladetto, Chiara Lobetti-Bodoni, Barbara Mantoan, et al.
Eclinicalmedicine|July 3, 2023
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencingStefania Oliva, Elisa Genuardi, Laura Paris, et al.
Hematological Oncology|August 21, 2020
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphomaIrene Della Starza, Lucia Anna De Novi, Marzia Cavalli, et al.
Pageof 5